TNFRSF17 and plasma cell myeloma: The CAR T-cell therapies, namely, Abecma® (idecabtagene vicleucel) and Carvykti® (ciltacabtagene autoleucel), focus on B-cell maturation antigen (BCMA) and target patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, and they ultimately expand the scope of CAR T-cell therapy indications across various hematological cancers (1–3).